Fiona Marshall, Ph.D., is set to leave Sosei. Marshall has served as CSO of the company since it bought Heptares but is now departing to take on a senior role at another business.
Sosei responded to the resignation of Marshall—who will leave at the end of next month—by giving Malcolm Weir, Ph.D., responsibility for its R&D activities. Weir, like Marshall, joined Sosei through the takeover of British GPCR specialist Heptares. Marshall and Weir co-founded Heptares and, as CSO and CEO, respectively, led it to a $400 million (£287 million) takeover by Sosei.
Since then, Heptares and its team have been integral to Sosei’s plans. Both Marshall and Weir hold EVP positions, with the former taking the CSO title and the latter serving as chief R&D officer. With Marshall departing, Sosei’s R&D activities will continue under Weir’s leadership.
Weir will get support from the newly promoted Tim Tasker, M.D. Tasker, who joined Heptares a year before the 2015 Sosei takeover, is now the Japanese company’s CMO and part of its executive team. The promotion of a doctor with decades of experience running trials at Evotec and GlaxoSmithKline comes at a time when Sosei is preparing to ramp up its clinical development activities.
“[Tasker’s] expertise is crucial to supporting our partnered programs and more importantly to drive our proprietary programs, of which we plan to advance at least six candidates into clinical studies over the next two years, including HTL0018318, our selective muscarinic M1 agonist, which we expect to start a phase 2 trial in patients with dementia with Lewy bodies in Japan during this year,” Sosei CEO Peter Bains said in a statement.
Shares in Sosei traded down 6% following news of Marshall’s departure.
By Nick Paul Taylor
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
